# Randomized, Controlled, Double-blind Multicenter Safety Study to Evaluate the Safety and Immunogenicity of Subcutaneous EPO HEXAL vs. ERYPO® in the Treatment of Anemia Associated With Chronic Renal Insufficiency in Predialysis Patients

> **NCT00701714** · PHASE3 · TERMINATED · sponsor: **Sandoz** · enrollment: 337 (actual)

## Conditions studied

- Anemia
- Chronic Renal Insufficiency

## Interventions

- **DRUG:** HX575 recombinant human erythropoietin alfa
- **DRUG:** ERYPO

## Key facts

- **NCT ID:** NCT00701714
- **Lead sponsor:** Sandoz
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-09
- **Primary completion:** 2009-07
- **Final completion:** 2010-01
- **Target enrollment:** 337 (ACTUAL)
- **Why stopped:** investigation of adverse events
- **Last updated:** 2018-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00701714

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00701714, "Randomized, Controlled, Double-blind Multicenter Safety Study to Evaluate the Safety and Immunogenicity of Subcutaneous EPO HEXAL vs. ERYPO® in the Treatment of Anemia Associated With Chronic Renal Insufficiency in Predialysis Patients". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT00701714. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*